+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07614061

A Phase I Open-Label Study Evaluating Safety and Efficacy of CD160-Enhanced Autologous BTC-Ag-T Cells in Advanced Biliary Tract Cancer

Led by Shanghai Zhongshan Hospital · Updated on 2026-05-29

18

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating an experimental T-cell therapy called BTC-Ag-T ACH-AgT001 for adults with advanced biliary tract cancer that cannot be removed by surgery or has spread to other parts of the body. This open-label, single-arm Phase 1 study aims to assess the safety, tolerability, and early signs of effectiveness of this therapy in patients who have not responded to standard treatments including chemotherapy combined with PD-1PD-L1 inhibitors. The treatment involves giving patients their own immune cells enhanced to target biliary tract cancer, called CD160-enhanced antigen-specific T cells, through intravenous infusion. Before the infusion, patients undergo lymphodepletion using a combination of cyclophosphamide and fludarabine. The study includes two parts Module A uses a dose-escalation approach to find the maximum tolerated dose, and Module B evaluates the safety of repeated lymphodepletion and re-induction at the chosen dose. Participants will be closely monitored throughout the study for side effects and response to treatment. Assessments include measuring tumor response and disease control over up to 24 months, and overall survival up to 36 months. Safety is followed through 30 days after the final infusion, with long-term follow-up planned for up to 15 years. Regular tests, imaging, and laboratory evaluations will track patient health and treatment effects during this extended observation period.

CONDITIONS

Brief Title

Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer

Research Team

G

Guoming Shi, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here